Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Event Logistics

- PMLiVE

Merck’s Keytruda regimen granted EC approval for expanded lung cancer use

The approval represents the sixth lung cancer indication for the anti-PD-1 therapy in Europe

- PMLiVE

Indegene announces acquisition of Trilogy Writing & Consulting

The deal is aimed at increasing Indegene’s clinical and regulatory writing expertise for global market authorisation applications

- PMLiVE

PMLiVE’s T40 – open for submissions!

Healthcare agencies can submit their entries free of charge with a deadline of 30 April

- PMLiVE

FDA grants Invivyd’s Pemgarda emergency use authorisation for COVID-19 prevention

The long-acting monoclonal antibody is authorised for use in adults and adolescents

- PMLiVE

Teva UK and Closed Loop Medicine partner to advance development of personalised medicines

The collaboration will utilise Closed Loop Medicine’s software as a medical device technology platform

- PMLiVE

dna Communications appoints Niamh Mangan as executive vice president and managing director

Mangan joins from 90TEN, where she most recently served as managing director

- PMLiVE

Remembering Paul Stuart-Kregor

Those who worked alongside Paul reflect on his dedication to the healthcare industry and his fellow pharma marketers

- PMLiVE

The anthropologists’ advantage

To impress at the strategic review, you first need to understand its hidden meaning

- PMLiVE

Do omnichannel approaches have a role in market access and payer discussions?

By Frank Fisher and Claire Woon

AMICULUM

- PMLiVE

How we provided comprehensive real-world patient data for PAH using Therapy Watch, our syndicated market tracking solution

PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such...

Research Partnership

- PMLiVE

Merck’s Winrevair granted FDA approval to treat pulmonary arterial hypertension in adults

The rare blood vessel disorder affects approximately 500 to 1,000 people in the US every year

- PMLiVE

AbbVie to expand inflammatory and autoimmune disease portfolio with $212.5m Landos acquisition

The deal will advance the clinical development of NX-13 for patients living with ulcerative colitis and Crohn’s disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links